Greenwich LifeSciences, Inc. (GLSI) stock
GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.70+4.94 (+35.90%)
Close on Nov 17, 2026Market cap $274.48MP/E –Yield –
Greenwich LifeSciences r&d expenses
Research and development expenses are spending on new products and technology.
Greenwich LifeSciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.30M, up 21.8% year over year. For fiscal 2025 it was $17.22M, up 11.2% from the year before. The highest annual figure on record is $17.22M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.22M | +11.2% |
| FY2024 | Dec 31, 2024 | $15.48M | +101.1% |
| FY2023 | Dec 31, 2023 | $7.70M | +18.9% |
| FY2022 | Dec 31, 2022 | $6.48M | +81.9% |
| FY2021 | Dec 31, 2021 | $3.56M | +236.6% |
| FY2020 | Dec 31, 2020 | $1.06M | -59.4% |
| FY2019 | Dec 31, 2019 | $2.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.56M | +4.2% |
| Q1 FY2026 | Mar 31, 2026 | $5.21M | +129.3% |
| Q4 FY2025 | Dec 31, 2025 | $8.27M | -4.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.27M | +42.5% |
| Q2 FY2025 | Jun 30, 2025 | $3.42M | +48.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.27M | +3.5% |
| Q4 FY2024 | Dec 31, 2024 | $8.69M | +272.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.29M | +6.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.31M | +67.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.19M | +20.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.33M | -5.1% |
| Q3 FY2023 | Sep 30, 2023 | $2.16M | +25.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.38M | +117.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.83M | +10.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.46M | +19.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.72M | +162.3% |
| Q2 FY2022 | Jun 30, 2022 | $633.25K | +13.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.66M | +489.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.06M | +244.6% |
| Q3 FY2021 | Sep 30, 2021 | $657.10K | +315.8% |
| Q2 FY2021 | Jun 30, 2021 | $556.53K | +269.0% |
| Q1 FY2021 | Mar 31, 2021 | $281.98K | +88.1% |
| Q4 FY2020 | Dec 31, 2020 | $598.88K | +131.5% |
| Q3 FY2020 | Sep 30, 2020 | $158.03K | -44.5% |
| Q2 FY2020 | Jun 30, 2020 | $150.80K | – |
| Q1 FY2020 | Mar 31, 2020 | $149.89K | – |
| Q4 FY2019 | Dec 31, 2019 | $258.67K | – |
| Q3 FY2019 | Sep 30, 2019 | $284.50K | – |
See a number that looks wrong?